For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Mouse Matrix Metalloproteinase-9 (MMP9) or gelatinase B is a precursor maturing into a 69 kDa, zinc- and calciumdependent, endopeptidase secreted by normal alveolar macrophages and granulocytes. MMP9 is secreted as a proenzyme (pro-MMP9) and is activated by proteolytic cleavage by serine proteases including other MMPs. In human, MMP9 is believed to act synergistically with MMP1 interstitial collagenase in the degradation of fibrillar collagens. MMP9 might contribute to the pathogenesis of joint destruction. MMP9 could also play a role in bone osteoclastic resorption and cancer metastasis. MMP9 constitutes a useful biomarker of disease status in arthritis and certain cancers.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
For the detection of three biomarkers in complex sample matrices, the AlphaLISA and Electrochemiluminescent (ECL) assay technologies were shown to have similar: Assay windows (linear dynamic range), Lower and upper detection limit, Intra-and inter-assay precision (lower % CV) The advantages of using AlphaLISA over ECL are: Shorter total assay duration No wash steps No shaking Lower sample volume requirement for equivalent performance Less expensive instrument and plates required
The AlphaLISA® assay is a homogeneous immunoassay alternative to classical ELISA. AlphaLISA assays were originally utilized to detect analytesin cell cultures upernatants or serum/plasma samples.
In a recent study, a team of international researchers used genomic data from modern human populations to better understand how humans have adapted to historical coronavirus outbreaks. They found evidence of an ancient coronavirus outbreak in East Asia over 20,000 years ago. Read on to see how these findings could help countries rethink the way they prepare for public health crises of the future.